Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified

Table 1 Baseline characteristics and treatment patterns of all patients

Characteristics	MBC		IDC-NOS		P value
	n = 188		n = 2,202
	n	%	n	%
Age (years)
≤40	31	16.5.	290	13.2	0.200
>40	157	83.5	1,912	86.8
Tumor size
T ≤2	82	43.4	623	28.3	<0.001
2< T ≤5	102	54.0	1,277	58.0
T >5	5	2.6	170	7.7
Unknown	0	0	132	6.0
Nodal status
0	132	70.2	1,130	51.3	<0.001
1 to 3	45	23.9	559	25.4
4 to 10	8	4.3	347	15.8
>10	3	1.6	110	5.0
Unknown	0	0	56	2.5
TNM stage
I	61	32.4	433	19.7	<0.001
II	117	62.2	1,537	69.8
IIA	102	54.3	1,253	56.9
IIB	15	8.0	284	12.9
III	10	5.3	215	9.8
Unknown	0	0	17	0.8
ER status
Negative	111	59.0	1,167	53.0	0.005
Positive	62	33.0	1,028	46.7
Unknown	15	8.0	7	0.3
PR status
Negative	82	38.0	1,100	50.0	0.005
Positive	119	55.1	1,053	47.8
Unknown	15	6.9	49	2.2
HR status
Negative	94	50.0	785	35.6	<0.001
Positive	79	42.0	1,395	63.4
Unknown	15	8.0	22	1.0
HER2/neu status
Negative	142	68.3	1,512	68.7	0.003
Positive	27	13.0	546	24.8
Unknown	39	18.8	144	6.5
Triple-negative
Yes	76	40.4	550	26.2	<0.001
No	107	56.9	1,610	71.8
Unknown	5	2.7	42	2.0
Surgery
Mastectomy	181	96.3	2,122	96.4	0.949
BCS	7	3.7	80	3.6
Chemotherapy
Undo	28	14.9	230	10.4	<0.001
Methotrexate included	73	38.8	857	38.9
Anthracyclin included	74	39.4	980	44.5
Taxane included	12	6.4	30	1.4
Others	1	0.5	10	0.5
Unknown	0	0	95	4.3
Radiotherapy
Undo	168	89.4	1,718	78.0	0.002
Do	18	9.6	402	18.3
Unknown	2	1.1	82	3.7
Hormonotherapy
Undo	125	66.5	1,216	55.2	0.002
Do	60	31.9	961	43.6
Unknown	3	1.6	25	1.1
p53
Negative	52	27.7	214	29.7	0.018
Positive	110	58.5	700	31.8
Unknown	26	13.8	848	38.5
Cathepsin-D
Negative	59	31.4	366	16.6	0.001
Positive	94	50.0	1,022	46.4
Unknown	35	18.6	814	37.0
PCNA
Negative	67	36.4	1,270	57.7	<0.001
Positive	87	47.3	484	22.0
Unknown	30	16.3	448	20.3

BCS, breasting-conserving surgery; ER, estrogen receptor; HER2/neu, human epidermal growth factor receptor 2; HR, hormone receptor; IDC-NOS, infiltrating ductal carcinoma-not otherwise specified; MBC, medullary breast carcinoma; PCNA, proliferating cell nuclear antigen; PR, progesterone receptor.

ISSN: 1477-7819